Cannabis shows anti-migraine benefits

In a recent study, published in Headache: The Journal of Head and Face Pain, researchers at University of California San Diego School of Medicine demonstrate for the first time in a placebo-controlled clinical trial that cannabis is effective to treat acute migraine.

Researchers found that vaporized cannabis containing 6% tetrahydrocannabinol (THC) and 11% cannabidiol (CBD) delivered significant relief: 67% of participants achieved pain reduction within two hours, 35% became completely pain free and benefits lasted up to 48 hours with no serious adverse events across 247 treated migraine attacks.

Study lead investigator Nathaniel Schuster, MD, professor of anesthesiology at UC San Diego School of Medicine and pain management specialist and headache neurologist at UC San Diego Health, is available to discuss the findings.

This study gives clinicians evidence-based data to guide their discussions with patients. It is important for people with migraine to know that the potencies we studied were low dosages, showing that a minimal amount of cannabis had anti-migraine benefits."

Nathaniel Schuster, MD, professor of anesthesiology, UC San Diego School of Medicine 

Source:
Journal reference:

Schuster, N. M., et al. (2025). Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial. Headache The Journal of Head and Face Pain. doi: 10.1111/head.70025. https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.70025

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cannabis legalization drives rising use among adults with historically lower consumption